DDDenise Ann Dayao

Denise Ann Dayao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Denise Ann Dayao has a total of 111 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Population Structure of Enterocytozoon bieneusi in Captive Macaques

    by Denise Ann E. Dayao, Debora R. Romualdo da Silva, Pyone P. Aye, Kathrine P. Falkenstein, Faith Schiro, Saul Tzipori, Giovanni Widmer

    Enterocytozoon bieneusi is a microscopic eukaryote classified in the phylum Microsporidia. It is the most common cause of human microsporidiosis. Over 300 diarrheic or soft fecal samples from captive macaques were screened by immunofluorescence for the presence of E. bieneusi spores and by PCR for E. bieneusi DNA. Fifty-three samples were identified as positive by both methods. Positive animals were significantly younger, but the infection did not negatively affect growth. With the goal of understanding the parasite’s population structure, we analyzed the E. bieneusi internal transcribed spacer (ITS) genotype. Classification of a total of 1,031,089 curated sequence contigs obtained from 53 samples showed the presence of sequences pertaining to three of the previously described eleven ITS genotypic groups. Indicative of mixed parasite populations, most E. bieneusi samples from individual macaques were characterized by ITS sequences belonging to several genotypic groups. Single-genotype isolates were the exception. The analysis of multiple samples from five macaques revealed a statistically highly significant clustering of ITS genotype by animal. The frequent occurrence of genotypically mixed ITS genotypes underscores the need for multiple curated genome sequences to support the unambiguous interpretation of sequences data and advance the study of this enigmatic pathogen.

  • Open Access

    Protection of Mice Orally Infected With Shiga Toxin–Producing Citrobacter rodentium Treated With Nanobody Multimer

    by Abhineet Sheoran, Amanda J Martinot, Sally R Robinson, Anne Fu, Cara Martone, Denise Dayao, Charles B Shoemaker, Saul Tzipori

    Shiga toxin (Stx)–producing Escherichia coli (STEC) colonizes the gut and causes enteritis through bacterial attachment-effacement (A/E), leading to mucosal damage. This facilitates systemic uptake of Stx, which can often lead to hemolytic-uremic syndrome (HUS) and acute renal failure, particularly in children <5 years of age. STEC infections expressing Stx2 variants are a major risk factor for HUS. Beyond patients receiving supportive care, there is no treatment for STEC-mediated HUS, and antibiotics are contraindicated. The 3- to 7-day prodromal interval between onset of STEC diarrhea and HUS offers a window for intervention for diarrheic patients, contacts thereof, or individuals exposed to the source of infection. Citrobacter rodentium (Cr), a mouse pathogen that exhibits mucosal bacterial A/E, was genetically constructed to express Stx2d (Cr-Stx2d). This, along with a Cr parent strain carrying the kanamycin gene, were used to model STEC in mice. Mice were treated intraperitoneally with a broad subtype-specific, Stx-neutralizing nanobody multimer fused to the human IgG1 Fc domain (VNA2-Stx/hFc). When a single treatment was administered as late as 4 days after Cr-Stx2d challenge, likely within the human STEC-HUS window of intervention, complete protection of mice was achieved. This Cr-Stx2d model, which mimics elements of human STEC infections by causing mucosal gut lesions and systemic Stx2d-mediated kidney damage, will help evaluate specific treatments against STEC-HUS, as demonstrated here with VNA2-Stx/hFc-treated mice given a single injection well after bacterial challenge. This product should be safe, simple, and economical to manufacture.

  • Open Access

    Structure-Guided Design of Calcium-Dependent Protein Kinase 1 Inhibitors for Cryptosporidiosis

    by Wissarut Wijitrmektong, Ryan Choi, Matthew A Hulverson, Lijun Liu, Anne Cooper, Kevin P Battaile, Elizabeth K Harmon, Denise Ann Dayao, Lauren Huerta, Saul Tzipori, et al.

    Background: Calcium-dependent protein kinase 1 (CDPK1) has emerged as a protozoan-specific target for the treatment of cryptosporidiosis. A previous study identified pyridopyrimidinones as new Cryptosporidium parvum CDPK1 (CpCDPK1) inhibitors with potent growth inhibition against C. parvum and Cryptosporidium hominis. Docking analyses suggested the unique positioning of the kinase's αC-helix could present refinement opportunities. Methods: Compounds designed to optimize the pyridopyrimidinones focused on the back-pocket region predicted to be proximal to the αC-helix, the solvent-exposed region, and the ATP ribose-binding site. Designed derivatives were synthesized and assessed for CpCDPK1 and Src kinase inhibition and for Cryptosporidium spp growth inhibition in mammalian cells. AMP/Mg+2 and 3 inhibitors were cocrystalized with CpCDPK1, and 2 inhibitors were profiled for kinase selectivity. Results: WIN 4-88 was identified with CpCDPK1 (half maximum inhibitory concentration [IC50] = 0.056 μM), and growth inhibition of zoonotic C. parvum NLuc (half maximum effective concentration [EC50] = 0.042 μM), anthroponotic C. parvum Tu114 (EC50 = 0.030 μM), and C. hominis Tu502 (EC50 = 0.062 μM), as well as enhanced kinome selectivity. The crystal structures confirmed the predicted binding mode, indicating key interactions with hinge residue Y155, similar orientations of the solvent-expose moieties, occupancy of the back pocket near the αC-helix, and for 1 inhibitor containing a solubilizing hydroxyethyl attached to the central heterocycle extension into the ATP ribose-binding site. Conclusions: The expanded structure-activity relationship and structural insights will potentially be applicable to other chemotypes with similar binding modes and will enhance development of CpCDPK1 inhibitors for the treatment of cryptosporidiosis.


  • Open Access

    An anti-Shiga toxin VHH nanobody multimer protects mice against fatal toxicosis when administered intramuscularly as repRNA

    by Sally R. Robinson, Denise Ann Dayao, Jhon A. Medina, Cara J. Martone, Anne K. Yauch, Troy Hinkley, Jesse H. Erasmus, Charles B. Shoemaker, Saul Tzipori

    Hemolytic uremic syndrome (HUS) is a systemic sequelae from gastrointestinal infection with Shiga toxin (Stx) producing Escherichia coli (STEC) that can result in acute kidney injury, lasting renal disease, and death. Despite a window for intervention between hemorrhagic diarrhea and onset of HUS, no specific therapies exist to prevent or treat HUS following STEC infection. Furthermore, there is no way to predict which patients with STEC will develop HUS or any rapid way to determine which Stx variant is present. To address this, we have broadened the therpay to neutralize additional toxin variants. It contains a multimer of nanobodies derived from camelid heavy chain antibody fragments (VHHs). An improved V HH-based n eutralizing a gent (VNA2) is delivered intramuscularly as RNA combined with LION nanoparticles rather than mRNA, that replicates on administration (repRNA), resulting in a rapidly circulating VNA that can bind systemic toxin. The RNA/VNA2-Stx administered intramuscularly prevents toxicity and death in a mouse model of acute Stx toxicity.


  • PI3Kγ inhibition circumvents inflammation and vascular leak in SARS-CoV-2 and other infections

    by Ryan M. Shepard, Anghesom Ghebremedhin, Isaraphorn Pratumchai, Sally R. Robinson, Courtney Betts, Jingjing Hu, Roman Sasik, Kathleen M. Fisch, Jaroslav Zak, Hui Chen, et al.

    Virulent infectious agents such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and methicillin-resistant Staphylococcus aureus (MRSA) induce tissue damage that recruits neutrophils, monocyte, and macrophages, leading to T cell exhaustion, fibrosis, vascular leak, epithelial cell depletion, and fatal organ damage. Neutrophils, monocytes, and macrophages recruited to pathogen-infected lungs, including SARS-CoV-2–infected lungs, express phosphatidylinositol 3-kinase gamma (PI3Kγ), a signaling protein that coordinates both granulocyte and monocyte trafficking to diseased tissues and immune-suppressive, profibrotic transcription in myeloid cells. PI3Kγ deletion and inhibition with the clinical PI3Kγ inhibitor eganelisib promoted survival in models of infectious diseases, including SARS-CoV-2 and MRSA, by suppressing inflammation, vascular leak, organ damage, and cytokine storm. These results demonstrate essential roles for PI3Kγ in inflammatory lung disease and support the potential use of PI3Kγ inhibitors to suppress inflammation in severe infectious diseases.


  • Open Access

    Systems genetics uncover new loci containing functional gene candidates in Mycobacterium tuberculosis-infected Diversity Outbred mice

    by Daniel M. Gatti, Anna L. Tyler, J Matthew Mahoney, Gary A. Churchill, Bulent Yener, Deniz Koyuncu, Metin N. Gurcan, Mk Khalid Niazi, Thomas Tavolara, Adam Gower, et al.

    Mycobacterium tuberculosis infects two billion people across the globe, and results in 8–9 million new tuberculosis (TB) cases and 1–1.5 million deaths each year. Most patients have no known genetic basis that predisposes them to disease. Here, we investigate the complex genetic basis of pulmonary TB by modelling human genetic diversity with the Diversity Outbred mouse population. When infected with M. tuberculosis, one-third develop early onset, rapidly progressive, necrotizing granulomas and succumb within 60 days. The remaining develop non-necrotizing granulomas and survive longer than 60 days. Genetic mapping using immune and inflammatory mediators; and clinical, microbiological, and granuloma correlates of disease identified five new loci on mouse chromosomes 1, 2, 4, 16; and three known loci on chromosomes 3 and 17. Further, multiple positively correlated traits shared loci on chromosomes 1, 16, and 17 and had similar patterns of allele effects, suggesting these loci contain critical genetic regulators of inflammatory responses to M. tuberculosis. To narrow the list of candidate genes, we used a machine learning strategy that integrated gene expression signatures from lungs of M. tuberculosis-infected Diversity Outbred mice with gene interaction networks to generate scores representing functional relationships. The scores were used to rank candidates for each mapped trait, resulting in 11 candidate genes: Ncf2, Fam20b, S100a8, S100a9, Itgb5, Fstl1, Zbtb20, Ddr1, Ier3, Vegfa, and Zfp318. Although all candidates have roles in infection, inflammation, cell migration, extracellular matrix remodeling, or intracellular signaling, and all contain single nucleotide polymorphisms (SNPs), SNPs in only four genes (S100a8, Itgb5, Fstl1, Zfp318) are predicted to have deleterious effects on protein functions. We performed methodological and candidate validations to (i) assess biological relevance of predicted allele effects by showing that Diversity Outbred mice carrying PWK/PhJ alleles at the H-2 locus on chromosome 17 QTL have shorter survival; (ii) confirm accuracy of predicted allele effects by quantifying S100A8 protein in inbred founder strains; and (iii) infection of C57BL/6 mice deficient for the S100a8 gene. Overall, this body of work demonstrates that systems genetics using Diversity Outbred mice can identify new (and known) QTLs and functionally relevant gene candidates that may be major regulators of complex host-pathogens interactions contributing to granuloma necrosis and acute inflammation in pulmonary TB.


  • Open Access

    Development of Two Mouse Models for Vaccine Evaluation against Cryptosporidiosis

    by Denise Ann Dayao, Justyna Jaskiewcz, Sangun Lee, Bruno Cesar Oliveira, Abhineet Sheoran, Giovanni Widmer, Saul Tzipori

    Cryptosporidiosis was shown a decade ago to be a major contributor to morbidity and mortality of diarrheal disease in children in low-income countries. A serious obstacle to develop and evaluate immunogens and vaccines to control this disease is the lack of well-characterized immunocompetent rodent models.


  • Reduced SARS-CoV-2 disease outcomes in Syrian hamsters receiving immune sera: Quantitative image analysis in pathologic assessments

    by Cesar Piedra-Mora, Sally R. Robinson, Lisa H. Tostanoski, Denise A. E. Dayao, Abishek Chandrashekar, Katherine Bauer, Linda Wrijil, Sarah Ducat, Tammy Hayes, Jingyou Yu, et al.

    There is a need to standardize pathologic endpoints in animal models of SARS-CoV-2 infection to help benchmark study quality, improve cross-institutional comparison of data, and assess therapeutic efficacy so that potential drugs and vaccines for SARS-CoV-2 can rapidly advance. The Syrian hamster model is a tractable small animal model for COVID-19 that models clinical disease in humans. Using the hamster model, the authors used traditional pathologic assessment with quantitative image analysis to assess disease outcomes in hamsters administered polyclonal immune sera from previously challenged rhesus macaques. The authors then used quantitative image analysis to assess pathologic endpoints across studies performed at different institutions using different tissue processing protocols. The authors detail pathological features of SARS-CoV-2 infection longitudinally and use immunohistochemistry to quantify myeloid cells and T lymphocyte infiltrates during SARS-CoV-2 infection. High-dose immune sera protected hamsters from weight loss and diminished viral replication in tissues and reduced lung lesions. Cumulative pathology scoring correlated with weight loss and was robust in distinguishing IgG efficacy. In formalin-infused lungs, quantitative measurement of percent area affected also correlated with weight loss but was less robust in non-formalin-infused lungs. Longitudinal immunohistochemical assessment of interstitial macrophage infiltrates showed that peak infiltration corresponded to weight loss, yet quantitative assessment of macrophage, neutrophil, and CD3+ T lymphocyte numbers did not distinguish IgG treatment effects. Here, the authors show that quantitative image analysis was a useful adjunct tool for assessing SARS-CoV-2 treatment outcomes in the hamster model.